Related Experiment Video
Updated: Jun 21, 2026

Analysis of Protein Folding, Transport, and Degradation in Living Cells by Radioactive Pulse Chase
Published on: February 12, 2019
Mechanisms for rescue of correctable folding defects in CFTRDelta F508
Diane E Grove1, Meredith F N Rosser, Hong Yu Ren
1Department of Cell and Developmental Biology and the UNC-Cystic Fibrosis Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Abstract:
Premature degradation of CFTRDeltaF508 causes cystic fibrosis (CF). CFTRDeltaF508 folding defects are conditional and folding correctors are being developed as CF therapeutics. How the cellular environment impacts CFTRDeltaF508 folding efficiency and the identity of CFTRDeltaF508's correctable folding defects is unclear. We report that inactivation of the RMA1 or CHIP ubiquitin ligase permits a pool of CFTRDeltaF508 to escape the endoplasmic reticulum. Combined RMA1 or CHIP inactivation and Corr-4a treatment enhanced CFTRDeltaF508 folding to 3-7-fold greater levels than those elicited by Corr-4a. Some, but not all, folding defects in CFTRDeltaF508 are correctable. CHIP and RMA1 recognize different regions of CFTR and a large pool of nascent CFTRDeltaF508 is ubiquitinated by RMA1 before Corr-4a action. RMA1 recognizes defects in CFTRDeltaF508 related to misassembly of a complex that contains MSD1, NBD1, and the R-domain. Corr-4a acts on CFTRDeltaF508 after MSD2 synthesis and was ineffective at rescue of DeltaF508 dependent folding defects in amino-terminal regions. In contrast, misfolding caused by the rare CF-causing mutation V232D in MSD1 was highly correctable by Corr-4a. Overall, correction of folding defects recognized by RMA1 and/or global modulation of ER quality control has the potential to increase CFTRDeltaF508 folding and provide a therapeutic approach for CF.
Insights
Inactivating RMA1 or CHIP ubiquitin ligases helps cystic fibrosis (CF) transmembrane conductance regulator (CFTR)DeltaF508 folding. Combining these with correctors enhances CFTR folding, offering a potential therapeutic strategy for CF.
Area of Science:
- Molecular Biology
- Cell Biology
- Genetics
Background:
- Cystic Fibrosis (CF) is caused by premature degradation of the CFTRDeltaF508 protein.
- Folding correctors are investigated as therapeutics, but the cellular environment's impact on CFTRDeltaF508 folding efficiency remains unclear.
Purpose of the Study:
- To investigate how cellular environment modulation affects CFTRDeltaF508 folding.
- To identify correctable folding defects in CFTRDeltaF508.
Main Methods:
- Inactivation of RMA1 or CHIP ubiquitin ligases.
- Treatment with the folding corrector Corr-4a.
- Analysis of CFTRDeltaF508 folding efficiency and localization.
Main Results:
- RMA1 or CHIP inactivation allowed CFTRDeltaF508 to escape endoplasmic reticulum retention.
- Combined inactivation and Corr-4a treatment enhanced CFTRDeltaF508 folding 3-7 fold compared to Corr-4a alone.
- RMA1 and CHIP recognize different CFTR regions, with RMA1 acting on nascent CFTRDeltaF508.
Conclusions:
- Modulating ER quality control by inactivating RMA1/CHIP can significantly improve CFTRDeltaF508 folding.
- Some, but not all, folding defects are correctable, suggesting targeted therapeutic approaches.
- This strategy holds potential for developing new CF therapies.
More Related Videos
Related Concept Videos
Protein Folding Quality Check in the RER
Molecular Chaperones and Protein Folding
The...
The Unfolded Protein Response
Export of Misfolded Proteins out of the ER
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Restarting Stalled Replication Forks

